Self- And Proxy-report To Impute The Ability To Walk

今后将进行旨在预防老年人残疾发作的临床试验，以检验各种干预措施。对于这项工作，至关重要的是要利用可重复的、有效的、对临床医生和老年人自己都有意义的残疾结果。行走400米的能力，通过客观的表现测试来衡量，已经被提议作为满足这些标准的结果。在临床试验中，无法确定结果事件是否在一部分人群中发生是一个严重的问题，它会降低研究的效力，导致研究结果的有效性丧失。本研究将为不能或拒绝进入诊所进行正式、客观的400米步行测试的临床试验参与者提供一种方法来推算这一结果。在这个方法学研究中，参与者将被问及一系列的自我报告项目，然后接受400米步行测试。代理人也将被问及参与者的行走习惯和能力。有了这些完整的数据，就可以确定哪些自我报告或代理项目，无论是单独的还是组合的，都可以用来估算步行400米的能力。一个特定的项目，一个项目的子集，一个量表，或者对整个问题的专家评判都是发展这种实际行走400米能力的潜在方法。这项试点研究将作出一些贡献，将感兴趣的一般老年病社区，将是至关重要的发展的行动不便预防临床试验。

Clinical trials aimed at preventing the onset of disability in older persons will be done to test a variety of interventions in the future. For this work, it is critical to utilize disability outcomes that are reproducible, valid, and meaningful to clinicians as well as older persons themselves. The ability to walk 400 meters, as measured using an objective test of performance, has been proposed as an outcome that meets these criteria. In clinical trials, the inability to determine if an outcome event has occurred in a portion of the population is a serious problem that reduces the power of the study and results in loss of validity of the findings. This research will provide a method of imputing this outcome for clinical trial participants who are unable or refuse to come into the clinic to undergo the formal, objective 400 meter walk test. In this methodologic study, participants will be asked a series of self-report items and then receive the 400 meter walk test. A proxy will also be asked about the walking habits and abilities of the participant. Having this complete data, it will then be determined what self-report or proxy items, either alone or in combination, can be used to impute ability to walk 400 meters. A specific item, a subset of items, a scale, or expert adjudication of the whole battery of questions are potential ways to develop this imputation of actual ability to walk 400 m. This pilot study will make a number of contributions that will be of interest to the general geriatric community and will be critical to the development of a clinical trial of mobility disability prevention.